Most Read Articles
Audrey Abella, 20 Dec 2019
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019. 
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
23 Dec 2019
The use of dienogest at 1 mg per day to treat primary dysmenorrhoea is well tolerated and attenuates symptoms of pain, as shown in the results of a phase II trial.

Product Highlight - Fluarix Tetra

30 Nov 2017

Fluarex Tetra - Inactivated quadrivalent influenza vaccine (split virion) vaccine (inj) 0.5 mL - GlaxoSmithKline

Flu vaccines help protect millions, but do you know there is a coverage gap?1
Choose Fluarix Tetra for your patients

  • The gap in B strain coverage from TIVs* can leave your patients unprotected.2,3,4,5
  • QIVs* can help to close the B strain coverage gap6,7
  • Fluarix Tetra is a QIV* which is generally well tolerated, is easy to administer, helps to increase protection against influenza B over TIVs*, closes the coverage gap to protect your patients and has robust data in high risk patients group6,8

*TIV: Trivalent Influenza Vaccine,QIV: Quadrivalent Influenza Vaccine

References:
1. United States Centers for Disease Control and Prevention. Quadrivalent Influenza Vaccine. Available at: https://www.cdc.gov/flu/protect/vaccine/quadrivalent.htm. Accessed on:3March 2017
2. Ambrose CS, Levin MJ. The rationale for quadrivalent infuenza vaccines Hum Vaccin Immunother 2012;8: 81-88
3. Jumat MR, et al. Genetic characterisation of in_uenza B viruses detected in Singapore, 2004 to 2009 BMC Res Notes 2014;7: 863
4. Belshe RB. The need for quadrivalent vaccine against seasonal influenza Vaccine 2010;28: D45–D53 5. Reed C, et al. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine Vaccine 2012;30: 1993-1998
6. GSK. Fluarix Tetra Quadrivalent influenza vaccine (split virion, inactivated). (2017).
7. Domachowske JB, Pankow-Culot H, Bautista M et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 years. J Infect Dis. 2013; 207: 1878–1887.
8. Kieninger D, Sheldon E, Lin W, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged 18 years. BMC Infectious Diseases 2013; 13:343.

Further information is available in section 12b, New in This Issue and mims.com.
Full prescribing information is available upon request.                        

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 20 Dec 2019
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019. 
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
23 Dec 2019
The use of dienogest at 1 mg per day to treat primary dysmenorrhoea is well tolerated and attenuates symptoms of pain, as shown in the results of a phase II trial.